Manufacturer and brand information of Teclistamab

Teritusumab (Teclistamab-cqyv) is an innovative antibody drug that has attracted great attention in the field of international hematological tumors in recent years. It is mainly used for the treatment of multiple myeloma (MM). The original manufacturer of this drug is Janssen Biotech, Inc., a subsidiary of the Janssen Pharmaceutical System of the Johnson & Johnson Pharmaceutical Group. Janssen has a relatively deep R&D accumulation in the field of tumor immunotherapy, especially in the direction of hematological malignancies, and continues to launch breakthrough targeted and immune drugs.

At the brand level, Teritusumab is sold under the trade name Tecvayli in overseas markets. In some Chinese materials and clinical communications, it is also called "Tecvayli". As a bispecific antibody drug, it is not positioned as a traditional chemotherapy or single-target targeted drug, but a new generation of T cell redirecting immunotherapy product, mainly for multiple myeloma patients who have received multiple lines of treatment in the past and have difficult disease control.

Judging from the progress of international marketing, teritusumab has been approved or conditionally used by regulatory agencies in many countries and regions such as Europe and the United States, and is used for patients with relapsed or refractory multiple myeloma under specific treatment backgrounds. Evaluations of the drug in overseas markets mainly focus on its innovative mechanism and immunotherapy concept, believing that it represents an important shift in the treatment of myeloma from "suppressing tumors" to "activating the autoimmune system to eliminate tumors."

In terms of supply and production, Janssen Pharmaceuticals is responsible for global production and quality management of teritusumab and follows international biologics production standards. As a highly complex biological drug, its production process, cold chain transportation and clinical use all have high requirements, which is one of the important reasons why its price and usage threshold are relatively high.

Keyword tags: teritusumab manufacturer, Teclistamab original drug, Teclistamab manufacturer, Janssen Biotech, new multiple myeloma drugs, teritusumab brand information

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli